Genzyme, Fovea sign blindness therapy deal

Genzyme and Paris-based Fovea Pharmaceuticals have forged a collaboration to develop gene therapies for blindness. The cross-Atlantic pact will match Genzyme's expertise in protein production and gene delivery with Fovea's expertise in retinal disease. They hope to advance new gene therapies for photoreceptor degeneration, a prime cause of blindness. No financial terms were disclosed. Fovea was launched two years ago.

"This first research partnership signed with Genzyme demonstrates the interest of our proprietary discovery platform," said Bernard Gilly, chairman and CEO of Fovea.

- see this release
- here's the report from the Boston Business Journal

Related Articles:
Is Carl Icahn out to buy Genzyme? Report
Boston officials herald big Genzyme expansion. Report
Fovea raises €20.5M. Report